All In MedTech

Device Trial Radar · NCT07178951

Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis

Safety and Feasibility of the Neurolyser XR Device for the Treatment of Predominantly Medial Chronic Knee Pain Due to Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Dec 31, 2026

Study completion Mar 30, 2027

Sponsor

Lead sponsor
FUSMobile Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 17, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.

Conditions

  • Osteoarthritis (OA) of the Knee
  • Knee Pain Arthritis
  • Chronic Knee Pain

Interventions

  • Neurotomy of the medial sensory articular branchesDevice

    Non-invasive thermal ablation of the medial sensory articular branches of the knee joint

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A positive clinical outcome will be measured by a 2-point reduction in the Numerical Rating Score (NRS)Time frame: Baseline score will be compared to post procedure intervals at 2 days, 7 days, 1 month, 3 months, and 6 months.
  2. Safety will be measured by the incidence and severity of treatment-related adverse events.Time frame: Adverse events will be evaluated at baseline and post procedure - 2 days, 7 days, 1 month, 3 months, and 6 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Unika Medical Centre

    North York, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.